The 2026 Healthtech Messaging Index
Holmusk
holmusk.com·scored November 1, 2026
19/38
Invisible
The page is doing some work, but the story isn't landing fast enough. Buyers and AI are both left guessing what makes Holmusk different.
The AI Recommendation Check
When we asked AI who to recommend for Real-world evidence (RWE) data platform for neuropsychiatry and behavioral health research, it named:
Buyer we put in the prompt: Head of Real-World Evidence, Medical Affairs Director, or HEOR lead at a life sciences company, or a neuropsychiatry researcher at an academic institution or health system. Both the buyer and the category were inferred from Holmusk’s homepage alone. The model had no web access.
Holmusk was on the list.
AI named them for their own category. That's the signal every homepage is supposed to send.
AI named you when asked who it recommends for "Real-world evidence (RWE) data platform for neuropsychiatry and behavioral health research", and described you accurately: "Holmusk is a data analytics company focused on behavioral health and neuropsychiatry real-world evidence, known for maintaining a large proprietary psychiatric patient database and offering analytics tools tailored to mental health research.". Your positioning is landing with the machines.
Overall assessment
Holmusk's biggest strength is its owned, named category asset ... the NeuroBlu database with specific scale numbers and a credible 'first-in-kind' NLP claim that makes it distinctly identifiable to AI and human buyers alike. Its biggest gap is a complete absence of social proof, customer outcomes, and cost-of-inaction framing ... the page reads as a data asset brochure with no proof that anyone has used it to achieve a specific result, which means the narrative never lands as bought evidence, only as sold capability.
Signal by category
Narrative Clarity
8 signals
Trust Signal
4 signals
AI Signal
6 signals
Conversion Signal
1 signal
Weakest signal · fix this first
07Cost of Inaction
“No mention of what happens to researchers, drug developers, or payers if they don't act ... no lost deals, delayed trials, or missed approvals cited.”
The page never names the cost of inaction ... no failed drug programs, no delayed approvals, no patient harm metrics from not having this data ... so the stakes are completely absent.
All 19 signals, scored 0 to 2.
Total 19/38
Narrative Clarity
8 signals
- 1
01The 7-Second Test
“Creating the standard for neuropsychiatry with best-in-class real-world evidence”
The vertical (neuropsychiatry) and mission are clear in 7 seconds, but who the buyer is and what specific problem is solved requires reading several paragraphs ... a caveman would not immediately grasp it.
- 1
02Rebellion / Movement
“There is currently no standardized way to measure symptoms or quality of care for neuropsychiatric conditions”
A named status quo problem exists (lack of standardization), but there is no named enemy, no explicit push against a competitor approach, and no rallying cry that frames this as a movement.
- 2
03Owned Language & Category
“NeuroBlu Database" ... "first-in-kind natural language processing models developed specifically for behavioral health”
Holmusk owns the named term 'NeuroBlu' as a brand/category anchor and claims the 'first-in-kind' NLP models for neuropsychiatry ... language an AI could quote back as distinctively theirs.
- 1
04ICP Clarity
“Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges”
Multiple buyer personas are named (researcher, clinician, payer, life sciences, government) but no role, company size, or stage is specified with enough precision for a visitor to immediately self-identify.
- 1
05Problem Leadership
“Neuropsychiatry needs better evidence to drive decision-making. There is currently no standardized way to measure symptoms”
The problem is stated early but in field-level clinical language rather than buyer-pain language ... it describes a field gap, not the buyer's felt frustration or business consequence.
- 1
06Solution Clarity
“We've built the field's largest, most robust source of clinical data for real-world data and a uniquely powerful evidence engine”
A visitor can roughly understand it's a real-world data platform for neuropsychiatry, but 'evidence engine' is vague and the one-sentence summary requires stitching together multiple paragraphs.
- 0
07Cost of Inactionweakest
“No mention of what happens to researchers, drug developers, or payers if they don't act ... no lost deals, delayed trials, or missed approvals cited.”
The page never names the cost of inaction ... no failed drug programs, no delayed approvals, no patient harm metrics from not having this data ... so the stakes are completely absent.
- 1
08Promised Land
“generate impactful evidence" ... "improved patient outcomes”
The promised land is gestured at (better outcomes, better decisions) but remains abstract ... no specific 'after' state like 'cut trial design time by X' or 'win formulary approval faster' is painted.
Trust Signal
4 signals
- 1
09Proof & Evidence
“1,300,000+ patients" "30+ geographically-diverse health systems" "20+ years of longitudinal data”
There are database size statistics, but no before/after deltas, no named outcomes from actual studies, and no evidence of customer results ... the numbers describe the product, not the proof.
- 0
10Social Proof
“No customer logos, named testimonials, case study titles, or video stories anywhere in the scraped content.”
Zero social proof elements are present ... no client names, no quotes with names and titles, no case studies ... making trust entirely self-asserted.
- 1
11Authority & Credibility
“first-in-kind natural language processing models developed specifically for behavioral health”
The 'first-in-kind' NLP claim hints at expertise but no founder credentials, published research citations, awards, or named experts are present to substantiate authority.
- 0
12Alternatives Acknowledged
“No mention of competitors, alternative approaches, or the 'do nothing' option anywhere on the page.”
The page makes no acknowledgment of competing solutions, incumbent databases, or the option to build in-house ... alternatives are entirely ignored.
AI Signal
6 signals
- 1
13Customer Focus
“Whether you're a researcher, a clinician, or a payer, we have a data-driven solution for your challenges”
The page oscillates between describing Holmusk's assets and gesturing at buyer personas but is predominantly capability-centric ('we've built,' 'we have captured') ... the customer is not the clear protagonist.
- 2
14AI-Parmesan Index
“first-in-kind natural language processing models developed specifically for behavioral health" extracting data from "unstructured clinical notes”
AI/NLP usage is described with a specific, mechanistic explanation ... what it does, on what data, for what purpose ... rather than a generic 'AI-powered' label sprinkled on the narrative.
- 1
15LLM Quotability
“The NeuroBlu Database enables researchers to build robust patient cohorts and conduct studies at an unprecedented level of granularity”
There are some declarative sentences but they rely on superlatives ('unprecedented') rather than precise, citation-ready claims with verifiable specifics an LLM would confidently quote.
- 0
16Copyright Freshness
“No visible dates on blog posts, case studies, or publications; no copyright year visible in the scraped content.”
No recency signals whatsoever are present in the scraped content, making it impossible for AI or human visitors to assess how current this information is.
- 2
17Entity Distinctiveness
“field's largest, most robust source of clinical data" for neuropsychiatry + "NeuroBlu" named brand + NLP models "specifically for behavioral health”
The combination of a named proprietary database (NeuroBlu), a neuropsychiatry-only focus, and first-in-kind NLP claims makes Holmusk distinctly describable ... an AI could not easily swap this description onto a generic RWE competitor.
- 2
18AI Recommendation Check
“AI described you as: "Holmusk is a data analytics company focused on behavioral health and neuropsychiatry real-world evidence, known for maintaining a large proprietary psychiatric patient database and offering analytics tools tailored to mental health research.”
AI named you when asked who it recommends for "Real-world evidence (RWE) data platform for neuropsychiatry and behavioral health research", and described you accurately: "Holmusk is a data analytics company focused on behavioral health and neuropsychiatry real-world evidence, known for maintaining a large proprietary psychiatric patient database and offering analytics tools tailored to mental health research.". Your positioning is landing with the machines.
Conversion Signal
1 signal
- 1
19Path & CTA Clarity
“GET STARTED" and "Contact us" CTAs present; no numbered process or soft secondary path visible.”
There is a primary CTA ('Get Started') and a secondary ('Contact Us') but no visible numbered steps or clear process explaining what happens next, so the path and the CTAs don't work together as a connected journey.
Keep the lead
AI already names Holmusk. The next edition decides if it still does.
Twenty minutes with Greg. Bring the page, bring the argument. You’ll leave knowing exactly which signal is costing Holmusk the AI recommendation, and what to write instead.
Not on the list? Run your homepage through the free Brand Signal Score and see where you’d land. Same 19 signals, same AI check, two minutes.